Maxim Group analyst Anthony Vendetti maintained a Buy rating on Joint Corp (NASDAQ: JYNT) today and set a price target of $10. The company’s shares closed yesterday at $8.66, close to its 52-week high of $8.88.
Vendetti noted:
“Market close, JYNT reported relatively inline adjusted EBITDA and GAAP EPS, on slightly lower-than-expected revenue. The company opened 8 franchise clinics in 2Q18, for a total of 365. It also executed one buy-back and now has a total of 48 corporate clinics. JYNT reiterated its 2018 guidance, including revenue of $31M-$32M. the company announced that CFO John Meloun resigned, effective to pursue other opportunities. CEO Peter Holt will serve as interim Principal Financial Officer as JYNT searches for a new CFO.”
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 9.3% and a 54.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Xtant Medical Holdings.
Joint Corp has an analyst consensus of Moderate Buy, with a price target consensus of $11.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.88 and a one-year low of $3.50. Currently, Joint Corp has an average volume of 79.46K.
Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through the Corporate Clinics and Franchise Operations segments. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics.
